NYMC Faculty Publications
Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?
DOI
10.1097/CRD.0000000000000245
Journal Title
Cardiology in Review
First Page
242
Last Page
248
Document Type
Article
Publication Date
October 2019
Department
Medicine
Abstract
Cholesterol metabolism and transport has been a major focus in cardiovascular disease risk modification over the past several decades. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) have been the most commonly used agents, with the greatest benefit in reducing both the primary and secondary risks of cardiovascular disease. However, heart disease remains the leading cause of death in both men and women in the United States. Further investigation and intervention are required to further reduce the risk for cardiovascular disease and cardiovascular-related deaths. This review will focus on high-density lipoprotein metabolism and transport, looking particularly at cholesteryl ester transfer protein (CETP) inhibitors. While studies of the other CETP inhibitors in its class have not shown a significant improvement in the prevention of primary or secondary cardiovascular risk, anacetrapib, the fourth and latest of the CETP inhibitors to be investigated, may be more promising.
Recommended Citation
Grabie, M., Tai, C., & Frishman, W. (2019). Is Anacetrapib Better Than Its CETP Inhibitor Counterparts?. Cardiology in Review, 27 (5), 242-248. https://doi.org/10.1097/CRD.0000000000000245